Richard E Gonsette

Summary

Country: Belgium

Publications

  1. ncbi request reprint Mitoxantrone in progressive multiple sclerosis: when and how to treat?
    R E Gonsette
    National Center for MS, Melsbroek B 1820, Belgium
    J Neurol Sci 206:203-8. 2003
  2. doi request reprint Boosting endogenous neuroprotection in multiple sclerosis: the ASsociation of Inosine and Interferon beta in relapsing- remitting Multiple Sclerosis (ASIIMS) trial
    Richard E Gonsette
    National Centre for Multiple Sclerosis, Vanheylenstraat 16, Melsbroek, Belgium
    Mult Scler 16:455-62. 2010
  3. pmc Self-tolerance in multiple sclerosis
    R E Gonsette
    Fondation Charcot Stichting, Avenue Huart Hamoir 48, 1030 Brussels, Belgium
    Acta Neurol Belg 112:133-40. 2012
  4. ncbi request reprint Endogenous neuroprotection in multiple sclerosis
    R E Gonsette
    National Centre for Multiple Sclerosis, Melsbroek, Belgium
    Acta Neurol Belg 110:26-35. 2010
  5. doi request reprint Neurodegeneration in multiple sclerosis: the role of oxidative stress and excitotoxicity
    R E Gonsette
    National Centre for Multiple Sclerosis, B 1820 Melsbroek, Belgium
    J Neurol Sci 274:48-53. 2008
  6. ncbi request reprint Oxidative stress and excitotoxicity: a therapeutic issue in multiple sclerosis?
    R E Gonsette
    National Centre for Multiple Sclerosis, B 1820 Melsbroek, Belgium
    Mult Scler 14:22-34. 2008
  7. ncbi request reprint Compared benefit of approved and experimental immunosuppressive therapeutic approaches in multiple sclerosis
    Richard E Gonsette
    National Centre for Multiple Sclerosis, B 1820 Melsbroek, Belgium
    Expert Opin Pharmacother 8:1103-16. 2007
  8. ncbi request reprint New immunosuppressants with potential implication in multiple sclerosis
    R E Gonsette
    National Center for Multiple Sclerosis, Vanheylenstraat 16, Melsbroek B 1820, Belgium
    J Neurol Sci 223:87-93. 2004
  9. ncbi request reprint Pixantrone (BBR2778): a new immunosuppressant in multiple sclerosis with a low cardiotoxicity
    R E Gonsette
    National Center for Multiple Sclerosis, Vanheylenstraat 16, B_1820, Melsbroek, Belgium
    J Neurol Sci 223:81-6. 2004
  10. ncbi request reprint A comparison of the benefits of mitoxantrone and other recent therapeutic approaches in multiple sclerosis
    Richard E Gonsette
    National Centre for Multiple Sclerosis, Melsbroek, Belgium
    Expert Opin Pharmacother 5:747-65. 2004

Detail Information

Publications11

  1. ncbi request reprint Mitoxantrone in progressive multiple sclerosis: when and how to treat?
    R E Gonsette
    National Center for MS, Melsbroek B 1820, Belgium
    J Neurol Sci 206:203-8. 2003
    ..To reduce the risk of cardiac events, the drug should be administered by slow infusion (over 30 min). Analogs of mitoxantrone with a much lower cardiotoxicity are currently investigated in animal experimental models...
  2. doi request reprint Boosting endogenous neuroprotection in multiple sclerosis: the ASsociation of Inosine and Interferon beta in relapsing- remitting Multiple Sclerosis (ASIIMS) trial
    Richard E Gonsette
    National Centre for Multiple Sclerosis, Vanheylenstraat 16, Melsbroek, Belgium
    Mult Scler 16:455-62. 2010
    ..We conclude that endogenous neuroprotective mechanisms recently identified in multiple sclerosis are complex and uric acid does not reflect the entire story...
  3. pmc Self-tolerance in multiple sclerosis
    R E Gonsette
    Fondation Charcot Stichting, Avenue Huart Hamoir 48, 1030 Brussels, Belgium
    Acta Neurol Belg 112:133-40. 2012
    ....
  4. ncbi request reprint Endogenous neuroprotection in multiple sclerosis
    R E Gonsette
    National Centre for Multiple Sclerosis, Melsbroek, Belgium
    Acta Neurol Belg 110:26-35. 2010
    ..Before experimental strategies are to become approved treatments further studies are necessary to understand the precise molecular mechanisms underlying neuroprotective pathways and their complex interconnections...
  5. doi request reprint Neurodegeneration in multiple sclerosis: the role of oxidative stress and excitotoxicity
    R E Gonsette
    National Centre for Multiple Sclerosis, B 1820 Melsbroek, Belgium
    J Neurol Sci 274:48-53. 2008
    ..The development of neuroprotective drugs is more problematic. Indeed, given the multiple and parallel mechanisms involved in neurodegeneration, modulation of a single specific pathway will likely yield a partial benefit if any...
  6. ncbi request reprint Oxidative stress and excitotoxicity: a therapeutic issue in multiple sclerosis?
    R E Gonsette
    National Centre for Multiple Sclerosis, B 1820 Melsbroek, Belgium
    Mult Scler 14:22-34. 2008
    ..Neutralization of oxidative stress and excitotoxicity, and in particular of peroxynitrite derived free radicals, might represent a therapeutic approach to provide neuroprotection in MS...
  7. ncbi request reprint Compared benefit of approved and experimental immunosuppressive therapeutic approaches in multiple sclerosis
    Richard E Gonsette
    National Centre for Multiple Sclerosis, B 1820 Melsbroek, Belgium
    Expert Opin Pharmacother 8:1103-16. 2007
    ..This review addresses the most recent data concerning the efficacy and safety of mitoxantrone and of new experimental therapies that are presently in progress...
  8. ncbi request reprint New immunosuppressants with potential implication in multiple sclerosis
    R E Gonsette
    National Center for Multiple Sclerosis, Vanheylenstraat 16, Melsbroek B 1820, Belgium
    J Neurol Sci 223:87-93. 2004
    ..Finally, a new concept about immunosuppressive treatments in organ transplantation, "tolerogenic immunosuppression", may have potential in MS...
  9. ncbi request reprint Pixantrone (BBR2778): a new immunosuppressant in multiple sclerosis with a low cardiotoxicity
    R E Gonsette
    National Center for Multiple Sclerosis, Vanheylenstraat 16, B_1820, Melsbroek, Belgium
    J Neurol Sci 223:81-6. 2004
    ..Safety data from animal studies and from phase II trials in cancer patients confirm a very weak cardiotoxicity, if any. A phase I trial with PIX in patients with a rapidly progressive MS seems thus warranted...
  10. ncbi request reprint A comparison of the benefits of mitoxantrone and other recent therapeutic approaches in multiple sclerosis
    Richard E Gonsette
    National Centre for Multiple Sclerosis, Melsbroek, Belgium
    Expert Opin Pharmacother 5:747-65. 2004
    ....
  11. ncbi request reprint Combination therapy for multiple sclerosis
    R E Gonsette
    National Centre for MS, B 1820 Melsbroek, Belgium
    Int MS J 11:10-21. 2004
    ....